Kilter Group’s Krystal Biotech KRYS Stock Holding History

Kilter Group’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$247	–	1635
2025 Q4	$247	Buy	+1	New	+$210	﹤0.01%	1277

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kilter Group's KRYS Position: Q1 2026 in Review

Kilter Group sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1 share — an estimated $247 sold.

Kilter Group first reported a position in KRYS in Q4 2025 and held it in 1 quarter. The position peaked at $247 in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Kilter Group reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
Kilter Group sold 1 Krystal Biotech share in Q1 2026, an estimated $247.
Kilter Group first reported a position in Krystal Biotech in Q4 2025 and held it in 1 quarter.
Kilter Group's Krystal Biotech position peaked at $247 in Q4 2025.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.